Editor’s highlights from the Journal of Comparative Effectiveness Research – January 2023
In this monthly column, I share some of my highlights from the latest issue of the Journal of Comparative Effectiveness Research, partner journal of The Evidence Base.
Happy New Year to all our readers! The new year brings a new issue of JCER, and we are excited to start volume 12 as a fully open access journal. All our content is now accessible to readers without the need for a subscription, and we look forward to reaching an even broader audience in 2023. In this month’s issue we are pleased to include two Plain Language Summary of Publication articles, and I highlight these, along with some of my other picks from Volume 12, Issue 1 below.
The views of teenagers with obesity, their caregivers, and doctors: a plain language summary of the ACTION Teens global survey
In their Plain Language Summary of Publication article, Mooney et al. (European Coalition for People Living with Obesity, Ireland) summarise the ACTION Teens global survey (published in the journal Pediatric Obesity); a survey carried out with nearly 13,000 people and including teenagers with obesity, their caregivers and doctors who provide their medical care. The survey highlights the importance of communication between these groups in order to best support teenagers with obesity.
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
In a further Plain Language Summary of Publication article, Richeldi et al. (Università Cattolica del Sacro Cuore, Italy) describe the main findings from a trial in people with idiopathic pulmonary fibrosis, recently published in the New England Journal of Medicine, examining the use of BI 1015550 as a potential treatment.
Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA
Multiple sclerosis (MS) has an unpredictable course and several different phenotypes. In their new research, Araujo et al. (Sanofi, MA, USA) describe the health economic outcomes of switching to alemtuzumab, a humanized monoclonal antibody approved for the treatment of relapsing forms of MS, from other disease-modifying therapies.
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
To inform clinical practice and healthcare decisions, it is important to determine the relative clinical value of available therapies for relapsed/refractory diffuse large B-cell lymphoma, the most common subtype of B-cell non-Hodgkin’s lymphoma. In their systematic review, Miller et al. (Broadstreet HEOR, Canada) evaluate trials of systemic therapies and the impact of patient characteristics on overall response rate.
I hope you enjoy these articles, along with the rest of the content in the January issue. Do get in touch if you’re interested in submitting to the journal or The Evidence Base in 2023!
